Abstract:Pancreatic adenocarcinoma (PDAC) is predominantly driven by KRAS oncogene. While all oncogenic KRAS mutations result in its hyperactivation, the allele-specific biology of KRAS mutations remain poorly understood. Addressing such issues has become particularly important with the recent advancements in the development of allele-specific and pan-KRAS inhibitors. Among the KRAS inhibitors, KRASG12C inhibitors (G12Ci), Sotorasib and Adagrasib, have been approved for treating KRASG12C-mutant lung cancer. Sotorasib also exhibited promising anticancer activity in human PDAC, with 21% response rate and over 70% patients experiencing certain level of tumor control. However, targeting KRAS oncogenes faces the major challenge of therapy resistance, which severely limited its survival benefit. While multiple studies have elucidated potential resistance mechanisms to G12Ci in lung cancer, the molecular mechanisms underlying its resistance in PDAC remains elusive, largely owing to the scarcity of relevant and faithful preclinical models. Here, we report the generation of a new autochthonous KRASG12C-driven PDAC model (p48Cre; LSL-KrasG12C; p53L/+, KCPC). Compared to the KRASG12D-driven KPC model (p48Cre; LSL-KrasG12D; p53L/+), tumor development in KCPC model is significantly delayed accompanied with corresponding decrease in both KRAS signaling and proliferation in premalignant lesions. As a result, the overall survival of the KCPC model is significantly prolonged compared to the KPC model, indicating allele-specific discrepancy of KRAS mutations during PDAC initiation. However, upon malignant progression, KRASG12C-driven mouse PDAC exhibit similar histopathological and molecular features as KRASG12D-driven tumors. Furthermore, similar to the clinical observation, KCPC tumors exhibit only partial response to Sotorasib treatment. CyTOF analysis indicates that such tumor persistence following G12Ci treatment occurs even in the presence of conversion from a 'cold' pro-tumor immune microenvironment to a 'hot' anti-tumor immune environment, as evidenced by the prominent increase in both cytotoxic T cells and M1-like macrophages. Interestingly, we discovered that the expression of CD24, which was recently identified as a new 'do not eat me' signal, is significantly upregulated on the surface of persist tumor cells, which suppresses the function of anti-tumor macrophages. Treatment with anti-CD24 blocking mAb enhanced macrophage-mediated phagocytosis in vitro and significantly sensitizes KCPC-derived xenograft tumors to Sotorasib treatment in vivo in a macrophage-dependent manner. Similar upregulation of CD24 following KRAS inhibition and therapeutic benefit of co-targeting CD24 and KRAS were also observed in KRASG12D-driven mouse and human PDAC, implicating the potential of such combination in a broader spectrum of KRAS-driven PDAC. Together, our findings revealed the allele-specific function of KRASG12C in the development of PDAC and identified a novel immune combination to improve the outcome of KRAS targeted therapy in PDAC. Citation Format: Yongkun Wei, Minghui Liu, Phuoc T. Nguyen, Dean N. Pan, Wantong Yao, Haoqiang Ying. KRASG12C exhibits allele-specific biology in pancreatic cancer and targeting CD24 sensitizes KRASG12C-driven tumors to sotorasib treatment [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Pancreatic Cancer; 2023 Sep 27-30; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(2 Suppl) nr C097.

Tailored modulation of stemness and drug resistance marker characteristics in K-Ras mutant lung cancer cells via PD-L1 gene suppression

KRAS Mutation Subtypes Responded Differently to Combination Immunotherapy Via Disturbing Myeloid-Derived Suppressor Cells in Non-Small Cell Lung Cancer.

CRISPR/Cas-Mediated Knockdown of PD-L1 and KRAS in Lung Cancer Cells

KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.

The Predictive And Prognostic Effects Of Pd-L1 Expression On Tki Treatment And Survival Of Egfr-Mutant Nsclc A Meta-Analysis

KRAS Mutants to Regulate PD-L1 Expression Through NF-ƘB and HIF-1α Pathways in Non-Small Cell Lung Cancer Cells.

Unraveling EGFR-TKI resistance in lung cancer with high PD-L1 or TMB in EGFR-sensitive mutations

CTLA4 blockade abrogates KEAP1 / STK11 -related resistance to PD-(L)1 inhibitors

Clinical Significance and Molecular Annotation for PD-L1 Negative Advanced Non-Small Cell Lung Cancer with Sensitivity to Responsive to Dual PD-1/CTLA-4 Blockade

Co-mutational status and PD-L1 expression in KRAS mutant non-small cell lung cancer (NSCLC): Role in treatment selection and association with clinical outcomes.

Bioinformatics and Experimental Validation for Identifying Biomarkers Associated with AMG510 (Sotorasib) Resistance in KRASG12C-Mutated Lung Adenocarcinoma

Abstract 6841: Mutation specific mechanisms of resistance to oncogenic KRAS inhibition

Characterization With KRAS Mutant Is a Critical Determinant in Immunotherapy and Other Multiple Therapies for Non-Small Cell Lung Cancer

Abstract 3867: Chromatin modification driving sub-clonal resistance to KRAS G12C combination therapies in KRAS mutant non-small cell lung cancer

PD-L1 Expression and Comprehensive Molecular Profiling Predict Survival in Nonsmall Cell Lung Cancer: A Real-World Study of a Large Chinese Cohort

KRAS G12V mutation upregulates PD‐L1 expression via TGF‐β/EMT signaling pathway in human non‐small‐cell lung cancer

Abstract C097: KRASG12C exhibits allele-specific biology in pancreatic cancer and targeting CD24 sensitizes KRASG12C-driven tumors to sotorasib treatment

Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas

Spatial multiplex analysis of lung cancer reveals that regulatory T cells attenuate KRAS-G12C inhibitor–induced immune responses

Effect on Non-Small Cell Lung Cancer After Combination of Driver Gene Mutations and Anti-PD -1/PD-L1 Immunotherapy as Well as Chemotherapy